Wed 30 Sep 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Ensure the website is using the HTTPS protocol.
Registered with the Digital Government Authority under number:
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients with Moderate-to-Severe Atopic Dermatitis in Gulf Countries: DERMIND-AD | Sanofi | Ongoing | Dupilumab | 4 | OBS18647 | 1.King Faisal Specialist Hospital and Researech Center - Jeddah 2. National Guard Hospital - Riyadh 3.King Abdulaziz University Hospital - Jeddah |
| REal-World Application of Luspatercept in Adults with Transfusion-Dependent beta-Thalassemia in the Middle East (RELATE): A non-interventional retrospective and prospective observational study | Bristol Myers Squibb | Ongoing | luspatercept | 4 | CA056-1107 | 1. Prince mohammed bin fahad hosputal - Qatif 2. King Saud University Medical city - Riyadh 3. Alnoor specialist hospital - Madinah 4. Hereditary Blood Disease Center - Alahsa |
| 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated | GSK Research & Development Limited | Ongoing | Efimosfermin alfa | 3 | 301160 | 1.King Fahad Specialist Hospital - Dammam 2.King Abdulaziz Medical City - Jeddah 3.Imam Abdulrahman Bin Faisal University - Dammam |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2) | GSK Research & Development Limited | Ongoing | Efimosfermin alfa | 3 | 306246 | 1.King Fahad Specialist Hospital - Dammam 2.King Faisal Specialist Hospital and Researech Center - Riyadh 3.King Abdulaziz Medical City - Jeddah 4.Imam Abdulrahman Bin Faisal University - Dammam |
| A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atumelnant in Adult Participants with Classic Congenital Adrenal Hyperplasia | Crinetics Pharmaceuticals, Inc. | Ongoing | atumelnant/ CRN04894 | 3 | CRN04894-12 | 1. King Faisal Specialist Hospital and Researech Center - Riyadh 2. National Guard Health Affairs - Riyadh 3.King Saud University Medical City - Riyadh 4.King Fahad Specialist Hospital - Dammam 5. King Abdullah International Medical research Center - Jeddah |
| A Multi-Center, Non-Interventional Study on Effectiveness and Treatment Persistence of Guselkumab in Patients with ULcerative Colitis and Crohn’s DiseasE in Real-World Practice in Saudi Arabia (EAGLE) | Johnson & Johnson Trading Limited | Ongoing | Tremfya (Guselkumab) | 4 | CNTO1959IB | 1. King Abdullah Medical City - Makkah 2. Integrated gut center - Jeddah |
| A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study with an open-label period and long-term extension to assess the efficacy and safety of rilzabrutinib in participants with warm autoimmune hemolytic anemia (wAIHA) | Arabia trading limited MB: Sanofi Arabia Trading Company Limited | Ongoing | Rilzabrutinib SAR444671 | 3 | EFC17360 | 1.King Saud University Medical City -Riyadh 2.King Faisal Specialist Hospital and Researech Center - Jeddah |
| A Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Atumelnant Treatment in Pediatric Participants with Congenital Adrenal Hyperplasia Including a Long-Term Extension | Crinetics Pharmaceuticals, Inc. | Ongoing | atumelnant/ CRN04894 | 2/3 | CRN04894-13 | 1.King Saud University Medical City -Riyadh 2. King Faisal Specialist Hospital and Research Center - Riyadh |
| Subcutaneous Fast Acting Insulin Versus Intravenous Regular Insulin Infusion in The Management of Moderate and Severe Diabetic Ketoacidosis Among Children with Type I Diabetes Mellitus: A Pilot Randomized Open Label-Controlled Trial | PI- initiated | Ongoing | Insulin Aspart | 3 | E-25-9801 | 1.King Saud University Medical City -Riyadh |
| A Phase 3,2-Part,Randomized,Double-Blind,Placebo-Controlled Study(Part 1)and Open-Label Extension(Part 2)to Evaluate the Efficacy,Safety,Pharmacokinetics,and Pharmacodynamics of Omaveloxolone(BIIB141)in Participants With Friedreich’s Ataxia Aged 2 to < 16 | Biogen Idec Research Limited | Ongoing | Omaveloxolone (BIIB141) | 3 | 296FA301 | 1.King Faisal Specialist Hospital and Researech Center - Riyadh |
Last update date: 14/09/2026 at 08:25 AM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.